Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Obesity: early-phase trial registry
306 of 1,057 indexed Obesity trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #3 of 28,707 conditions by registered trial count.
1,057 US clinical trials · 306 currently recruiting · #3 of 28,707 conditions by registered trial count
Obesity: 1,057 US clinical trials tracked, 306 recruiting.
Obesity is the subject of 1,057 registered US clinical trials on ClinicalTrials.gov, 306 of them currently open to new participants. 107 are in Phase 3-4 (later-stage) and 196 in Phase 1-2 (earlier-stage). The most active sponsor is Eli Lilly and Company, running 48 of these trials.
Enrollment posture brief
Registry condition obesity
OPEN 306 | RECR 29% | LATE 107 | EARLY 196 | RANK #3 | SPON 48
Volume-matched condition peers
Nearest open-share peer: Metastatic Pancreatic Adenocarcinoma (29% recruiting · 38 trials)
Obesity lists 306 open slots (29% of 1,057 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Obesity on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Obesity is recruiting below its size-band peers.
306 of 1,057 indexed trials (28.9%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Obesity trials is spread across many organizations.
Eli Lilly and Company accounts for 48 of 1,057 trials (4.5%). 314 distinct sponsors appear on at least one study for this condition label.
-
Typical Obesity enrolment sits around 90 participants.
Median target enrolment is 90 among the 1,054 trials that report a genuine target (sentinel values excluded). 555 of those (52.7%) plan for fewer than 100 participants.
-
Obesity research is mostly interventional.
894 interventional and 163 observational studies make up this index (84.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
1,057 total, page 3 of 22
Heart Health Study in Washington D.C. to Develop a Community-Based Behavioral Weight Loss Intervention
National Heart, Lung, and Blood Institute (NHLBI)
NCT01927783
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
Eli Lilly and Company
NCT07215559
RemI for Post-Bariatric Surgery Weight Regain
Temple University
NCT06292936
Stand Up for Your Health with a Sit-stand Desk
Medical College of Wisconsin
NCT05585190
Semaglutide for Post-Smoking Cessation Weight Management
The University of Texas Health Science Center, Houston
NCT06173778
Transdiagnostic Intervention to Reduce Internalized Health-Related Stigma
University of Florida
NCT05561595
Comparing the Efficacy and Safety of the EndoZip System and Apollo ESG in Obese Patients
Nitinotes Surgical
NCT07090005
Testing an Integrated PTSD and Weight Management Intervention: A Hybrid Type 1 Trial
VA Office of Research and Development
NCT07010757
Optimizing Telehealth-delivery of a Weight Loss Intervention in Older Adults
University of North Carolina, Chapel Hill
NCT06044571
Optimization of Chrononutrition to Reduce the Risk of Disease in Shift Workers
Salk Institute for Biological Studies
NCT06891352
Stepped Care for Weight Loss Maintenance
Johns Hopkins University
NCT06151145
A Study on How NNC0174-1213 Works in People With Overweight or Obesity.
Novo Nordisk A/S
NCT06719011
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
University of Michigan
NCT06007404
Daily Eating Patterns for Total Health Study
The University of Tennessee, Knoxville
NCT06455995
Motivating Increases in Physical Activity for Prevention of Weight Regain After Metabolic Bariatric Surgery
Hartford Hospital
NCT06484621
Pharmacological and Behavioral Treatment After Bariatric Surgery
Yale University
NCT05157698
Single Nuclei RNA-seq to Map Adipose Cellular Populations and Senescent Cells in Older Subjects
Cedars-Sinai Medical Center
NCT05653258
PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis
University of Alabama at Birmingham
NCT04971720
Sit Less, Interact and Move More (SLIMM) 2 Study
Srinvasan Beddhu
NCT05173714
Investigating the Impact of Obesity on Pubertal Development in Girls
National Institute of Environmental Health Sciences (NIEHS)
NCT02583646
Endoscopic Sleeve Gastroplasty (ESG) for the Treatment of Obesity
The Methodist Hospital Research Institute
NCT06339320
Validation of a Novel Cerebellar-striatal Satiety Circuit in Humans
Brigham and Women's Hospital
NCT06105164
Endoscopic Ultrasound Shear Wave Elastography in Patients With Non-alcoholic Fatty Liver Disease
Brigham and Women's Hospital
NCT05728697
MEHMO Natural History and Biomarkers
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NCT06019182
Modifying Adiposity Through Behavioral Strategies to Improve COVID-19 Rehabilitation
VA Office of Research and Development
NCT05880108
Pilot Study of Isocaloric Time Restricted Eating on Ketone Metabolism and Immunoregulation
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT06169137
Program for Fully Understanding Eating and Lifestyle Change (FUEL)
The Miriam Hospital
NCT05562427
RESCUE: Discontinuation of GLP-1
Boston Scientific Corporation
NCT07190794
Effects of Brain Stimulation on Food Intake and Behavioral Weight Loss Treatment
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT00739362
A Culturally-relevant Micronutrient-dense Plant-rich (mNDPR) Dietary Intervention for Native Americans
Northern Arizona University
NCT04755062
A Novel Obesity Prevention Program for High-Risk Infants in Primary Care
Children's Hospital Medical Center, Cincinnati
NCT06028113
Project VIBE: Virtual Intervention for Binge Eating in Adolescents
University of Pittsburgh
NCT06819813
First in Human Study in Subjects With Obesity, But Otherwise Healthy
NeuroBo Pharmaceuticals
NCT06252220
A Study of a Novel Precision Medicine Approach For Obesity
Mayo Clinic
NCT06814938
Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial
Pichamol Jirapinyo, MD, MPH
NCT06138821
EMPOWER: Effects of Weight Loss and Exercise Post-stroke
Medical University of South Carolina
NCT05901675
Evaluation of Milk Polar Lipids in Dyslipidemic Adults With Abdominal Obesity
University of Connecticut
NCT05700916
Transpulmonary Pressure Guided Mechanical Ventilation Weaning in Obesity
University of Mississippi Medical Center
NCT05530434
Glucagon-Like Peptide-1 Receptor Agonist in ADPKD
University of Colorado, Denver
NCT06582875
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
Eli Lilly and Company
NCT06672549
A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
Eli Lilly and Company
NCT06672939
tDCS With Cognitive Training to Reduce Impulsivity and Weight in Veterans With Obesity
VA Office of Research and Development
NCT05225233
Bone Metabolism in 12-21 Year Olds Undergoing GLP-1 Receptor Agonist Therapy
University of Virginia
NCT06903923
Exercise Training and Fat Metabolism in Postmenopausal Women
Florida State University
NCT05351476
Dietary Intervention to Improve Kidney Transplant Outcomes
University of California, Davis
NCT05449496
Weight Loss Study: Genetics and Response to Naltrexone/Bupropion
Columbia University
NCT05919797
Fibrosis Lessens After Metabolic Surgery
Ali Aminian
NCT06374875
A Study of LY3549492 in Healthy Participants and Participants With Overweight or Obesity
Eli Lilly and Company
NCT07232732
Thermogenic Silencer Regulatory Factors in Humans
Rockefeller University
NCT06424132
The Effects of Increasing Caloric Intake on Diet-Induced Thermogenesis and 24h Energy Expenditure
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT05545306
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 95 |
| Phase 2 | 101 |
| Phase 3 | 69 |
| Phase 4 | 38 |
Top Sponsors
Named interventions
Most-linked intervention names on Obesity records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Obesity trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Obesity page
1,057 registered trials, 306 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 306 Obesity trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Eli Lilly and Company sponsors the most Obesity trials on record, review their full trial history before evaluating a specific study. See Eli Lilly and Company's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Obesity condition card totals 1,057 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.